Italy Drug Delivery Devices Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Italy Drug Delivery Devices Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The Italian drug delivery devices market is expected to register a CAGR of 22.4% over the forecast period.

Key Highlights

• The Italian drug delivery devices market has been significantly impacted by the COVID-19 pandemic because of the development of COVID-19 vaccinations and treatments, which has raised the market's need for needles and syringes for drug delivery devices. For instance, in September 2022, the distribution of Moderna and Pfizer-BioNTech COVID-19 vaccines designed to stop the spread of the Omicron version of the virus was approved by AIFA in Italy.
• The rising prevalence of chronic diseases and the development of new drugs and biologics are key factors driving the Italian drug delivery devices market growth. Drug delivery devices deliver the drugs that are beneficial for the targeted population to recover fasUsingage of these drug delivery devices reduces the chances of side effects by improving the drug present at the target site. This helps in reducing the dose and associated side effects.
• In addition, a rising number of chronic diseases like diabetes across the region will promote the adoption of drug-delivery devices and drive the overall market. As per IDF Diabetes Atlas, 2021, the age-adjusted comparative prevalence of diabetes in Italy was estimated as 6.4%, 7.4%, and 8.0% for 2021, 2030, and 2045, respectively. The presence of a huge target population will require regular drug delivery devices for diagnosis and treatment purposes and propel the drug delivery devices market. Similarly, the rising burden of chronic diseases increases the demand for targeted therapy, which is majorly administered through the injectable route of administration. Moreover, increasing R&D expenditure by innovators and market players and technological advancements in understanding human biology and diseases will fuel the overall market.
• However, the risk of needlestick injuries is restraining the growth of the Italian drug delivery devices market.

Italy Drug Delivery Devices Market TrendsInjectable Under Route of Administration is Estimated to Witness Healthy Growth Over the Forecast Period

An injection is an act of administering a liquid, especially a drug, into a person's body using a needle and a syringe. The primary purpose of injectable drug delivery is to get an immediate onset of action of the drug and for direct administration of the drug to the systemic circulation. The primary factor attributed to the high growth of the injectable drug delivery device segment is the growing burden of chronic disease and the convenience associated with the device.

The new developments in the region's prevention and treatment of chronic diseases drive the market over the forecast period. For instance, as per the ANSA Corporate, in August 2022, an Italian research team created a cancer vaccine that can stimulate immune responses against tumors and improve the efficiency of immunotherapy medications. The vaccine uses a virus as a trojan horse. Thus, the new vaccine developments need injectable drug delivery devices to administer and are expected to positively impact the market over the forecast period.

Similarly, advanced drug delivery devices among the injectable segment and the collaborations of major players are expected to impact the market over the forecast period positively. For instance, in April 2022, Italian-based Stevanato Group SpA and Bexson Biomedical Inc. signed an agreement expanding their collaboration that would grant Bexson access to the use of Stevanato’s wearable delivery system a customized version of the SG EZ-be Pod. SG EZ-be Pod is a small, wearable subcutaneous drug delivery device that can be programmed for a wide range of medications and delivery profiles, including at-home delivery.

Thus, due to the aforementioned factors, the administration segment's injectable route is expected to grow significantly over the forecast period.

Infectious Diseases Under Application is Estimated to Witness Highest CAGR Over the Forecast Period

Infectious diseases are disorders caused by organisms such as bacteria, viruses, fungi, or parasites. The increasing burden of infectious diseases like HIV, shingles, tuberculosis, and others in Italy increases the demand for treatment using various drug-delivery devices and drives the market over the study period.

For instance, as per the report published by Beyond Rheumatology in July 2022, the yearly incidence of shingles (Herpes Zoster) in those under 50 years old in Italy is 6.46 cases per 1,000 person-years. Herpes Zoster incidence rises with age. Also, given that varicella-zoster virus infection puts 90% of adults at risk for getting shingles, the disease affects at least 1 in 3 people throughout their lifetimes. Hence with the increasing burden of infections, preventive measures should be taken through vaccinations using various injectable drug delivery devices that may drive the segment growth over the study period.

Furthermore, as per the report published by Human Vaccines & Immunotherapeutics in September 2021, the recombinant zoster vaccine is preferable over the zoster live vaccine for the prevention of herpes zoster (HZ) and associated problems. Moreover, as reported in the Ministerial Circular dated March 2021, a new recombinant adjuvanted -RZV vaccine against HZ is available in Italy through the public channel. Hence novel and advanced preventive options for infectious diseases using vaccination increase the usage of injectable drug delivery devices, which is expected to boost the segment growth over the forecast period in the country.

Italy Drug Delivery Devices Market Competitive Analysis

The Italian drug delivery devices market is moderately competitive and consists of several major players. Some of the companies currently dominating the market are Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services Inc., Gerresheimer AG, BD (Becton, Dickinson, and Company), Baxter, Teva Pharmaceutical Industries Ltd, and Viatris Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.